• Shuxia Ge, Qianqian Xing, Anqi Zhang, and Yucui Wang.
• Department of Obstetrics and Gynecology, Liaocheng People's Hospital.
• Medicine (Baltimore). 2021 Jan 15; 100 (2): e23904e23904.

BackgroundTraditional Chinese medicine (TCM) has been widely applied as promising adjunctive drugs for ovarian carcinoma (OC) in China and other Asian countries. However, its exact clinical efficacy and safety is still not well investigated. In this study, we aimed to summarize the efficacy of TCM on survival, quality of life (QoL), and immune function in patients with OC through the meta-analysis.MethodsRelevant clinical trials of TCM for the treatment OC patients will be searched in Cochrane Library, Web of Science, Google Scholar, PubMed, Medline, Embase, China Scientific Journal Database, China National Knowledge Infrastructure, Chinese Biomedical Literature Database, and Wanfang Database from their inception to November 2020. Two researchers will perform data extraction and risk of bias assessment independently. The clinical outcomes, including overall survival (OS), QoL, immune function, tumor markers, and adverse events, were systematically evaluated by using Review Manager 5.3 and Stata 14.0 statistical software.ResultsThe results of this study will provide high-quality evidence for the effect of TCM on survival, QoL and immune function in patients with OC.ConclusionThe conclusions of this meta-analysis will be published in a peer-reviewed journal, and draw an objective conclusion of the efficacy of TCM on survival, QoL, and immune function in patients with OC.Trial Registration NumberINPLASY2020110104.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

37 keywords...

hide…